Regardless of the molecular subtype, patients with previously treated advanced gastric cancer with a PD-L1 combined positive score (CPS) ≥ 1 show a significantly higher overall response rate to immune checkpoint inhibitors than PD-L1-negative patients. Here, CD274 is linked to gastric cancer.